BCL2 and diffuse large B-cell lymphoma: In contrast, MYC+ or BCL2+ expression in DLBCL correlated with significantly poorer survival for the overall patient cohort (P < 0.0001, Figure 4A–4B) and for patients with GCB (MYC+: P < 0.0001, Figure 4D; BCL2+: P = 0.004, Figure 4E) and ABC subtypes of DLBCL (MYC+: P = 0.032, Figure 4G; BCL2+: P < 0.0001, Figure 4H).